The FDA assessed the protection and performance of atidarsagene autotemcel according to knowledge from 37 children who obtained atidarsagene autotemcel in two solitary-arm, open-label medical trials and in an expanded access application.[7] Small children who received remedy with atidarsagene autotemcel have been as compared to untreated children (